Prime Medicine PRME Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | $838K-61.6% | $1.23M+486% | $1.12M— | $1.45M+146% | ||
| $34.11M-15.9% | $34.71M+1.8% | $43.99M+9.0% | $41.38M-3.9% | $40.56M+7.4% | ||
| $17.41M+31.0% | $14.74M+19.8% | $11.21M-20.5% | $13.12M+4.1% | $13.28M+19.1% | ||
| $51.51M-4.3% | $49.45M+6.6% | $55.2M+1.4% | $54.49M-2.1% | $53.85M+10.0% | ||
| -$50.65M+3.3% | -$48.61M-9.9% | -$53.97M+0.5% | -$53.38M+4.1% | -$52.39M-8.4% | ||
| $1.53M+205% | $2.53M+30.0% | $3.39M+97.8% | $786K+273% | $502K-81.5% | ||
| -$49.12M+5.3% | -$46.08M-9.0% | -$50.58M+3.7% | -$52.59M+4.9% | -$51.89M-13.4% | ||
| -$0.28+30.0% | -$0.24+22.6% | -$0.32+27.3% | -$0.41+10.9% | -$0.40+9.1% | ||
| -$48.8M+3.7% | -$46.73M-9.9% | -$52.09M+1.1% | -$51.51M+4.8% | -$50.69M-7.8% | ||
| -$50.65M+3.3% | -$48.61M-9.9% | -$53.97M+0.5% | -$53.38M+4.1% | -$52.39M-8.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Prime Medicine profitable?
- Prime Medicine is not currently profitable: it reported a net loss of $198.4M over the trailing twelve months, a -4342.4% net margin.
- What is Prime Medicine's earnings per share?
- Prime Medicine's diluted EPS over the trailing twelve months is $-1.25.
- Where does Prime Medicine's income statement data come from?
- Every line is extracted from Prime Medicine's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.